Related Experiment Video
Updated: Apr 25, 2026
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Estradiol measurement in translational studies of breast cancer
1Institute of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Abstract:
Plasma estrogen measurement with use of radioimmunoassays has been instrumental in the development of aromatase inhibitors for endocrine therapy of postmenopausal breast cancer. However, due to low plasma estrogen concentrations in postmenopausal women, direct radioimmunoassays lack the sensitivity required. While certain laboratories have developed highly sensitive assays for research purposes revealing plasma estrogen suppression consistent with results from tracer studies, such assays are time and labor-consuming due to need for pre-analytical chromatographic purification, sample concentration and sometimes conversion of precursors to products. While novel chromatographic methods involving mass spectrometry analysis are likely to replace such radioimmunoassays in the future, so far a limited number of laboratories have developed suitable assays with a detection limit (around 1 pM) that is required for analyzing plasma estrogen levels in patients during treatment with potent aromatase inhibitors.
Insights
Accurate measurement of plasma estrogen is crucial for breast cancer endocrine therapy. Current methods lack sensitivity for postmenopausal women, necessitating advanced techniques for precise monitoring during aromatase inhibitor treatment.
Area of Science:
- Endocrinology
- Oncology
- Analytical Chemistry
Background:
- Radioimmunoassays for plasma estrogen are vital for developing aromatase inhibitors in breast cancer therapy.
- Low estrogen levels in postmenopausal women challenge the sensitivity of direct radioimmunoassays.
- Existing sensitive assays are labor-intensive, requiring extensive pre-analytical processing.
Purpose of the Study:
- To highlight the limitations of current plasma estrogen measurement techniques in postmenopausal breast cancer patients.
- To emphasize the need for highly sensitive assays for monitoring aromatase inhibitor therapy.
- To discuss the potential of novel mass spectrometry-based methods.
Main Methods:
- Review of existing radioimmunoassay techniques for plasma estrogen.
- Discussion of limitations including sensitivity and pre-analytical requirements.
- Exploration of emerging chromatographic and mass spectrometry methods.
Main Results:
- Direct radioimmunoassays lack the sensitivity for low estrogen levels in postmenopausal women.
- Highly sensitive research assays exist but are time-consuming and labor-intensive.
- Few laboratories have developed assays with the required 1 pM detection limit for potent aromatase inhibitor monitoring.
Conclusions:
- Sensitive and efficient plasma estrogen measurement is critical for effective endocrine therapy in postmenopausal breast cancer.
- Novel mass spectrometry-based assays are expected to overcome current limitations.
- Further development is needed to make highly sensitive assays widely accessible for clinical use.
